Multiple drugs

COVID-19: 4 case reports

    Author Information

    An event is serious (based on the ICH definition) when the patient outcome is:

    • * death

    • * life-threatening

    • * hospitalisation

    • * disability

    • * congenital anomaly

    • * other medically important event

    “ ”

    In a transversal study of 196 patients (study name: emcovid-19), four patients [ages and sexes not stated] were described, who developed COVID-19 during immunomodulatory treatment with alemtuzumab (1 patient), cladribine (1 patient), interferon-β (1 patient) and ocrelizumab (1 patient) for multiple sclerosis [routes, dosages, durations of treatments to reactions onsets and outcomes not stated]. All patients had positive IgG antibodies for SARS-COV-2. Patients with interferon-β (n=1) and ocrelizumab (n=1) were symptomatic and the patient with ocrelizumab treatment required hospitalisation because of COVID-19.

    Reference

    1. Hervas-Garcia JV, et al. Seroprevalence of SARS-cOV-2 in multiple sclerosis patients under immunomodulatory treatment in lleida (study emCOVID-19). Multiple Sclerosis Journal 26 (Suppl.): 59 abstr. LB1163, No. 3, Dec 2020. Available from: URL: http://doi.org/10.1177/1352458520974938

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Multiple drugs. Reactions Weekly 1843, 247 (2021). https://doi.org/10.1007/s40278-021-91349-z

    Download citation